Last updated: February 19, 2026
What Is the Drug Identified by NDC 21922-0069?
The National Drug Code (NDC) 21922-0069 corresponds to [Drug Name], a [drug class, e.g., monoclonal antibody, small molecule, biologic, etc.]. The drug is indicated for [primary indications, e.g., metastatic melanoma, rheumatoid arthritis, etc.]. It is marketed by [Manufacturer Name] and approved by the FDA as of [approval date].
Market Landscape Overview
Market Size and Penetration
The drug targets a [specific patient population, e.g., adult patients with advanced melanoma]. Market size is driven by prevalence estimates:
| Metric |
2023 Data |
Source |
| U.S. prevalence |
[Number] patients |
[Centers for Disease Control and Prevention (CDC), 2022] |
| Annual incidence |
[Number] cases |
[National cancer registries] |
| Treatment rate |
[Percentage]% of eligible patients |
[Published market reports, IQVIA] |
Global expansion occurs primarily in [regions, e.g., Europe, Asia-Pacific], contingent on regulatory approvals.
Competitive Environment
Key competitors include:
- [Competitor 1, e.g., Drug A]
- [Competitor 2, e.g., Drug B]
- [Competitor 3, e.g., Drug C]
Market share is concentrated among [top 2-3 players], each holding approximately [percentage]%, with new entrants pursuing indications expansion.
Key Market Drivers
- Unmet medical needs in resistant or refractory cases
- Regulatory approvals expanding indications
- Increasing diagnostic testing leading to earlier detection
Challenges
- Patent expirations expected in [year]
- Price competition from biosimilars and generics
- Reimbursement hurdles in certain markets
Price Analysis and Projections
Current Pricing
As of Q1 2023, wholesale acquisition cost (WAC) for NDC 21922-0069 is approximately $[price] per [dosage unit, e.g., vial, treatment course]. The average monthly treatment cost ranges from $[lower] to $[upper],** depending on dosage and administration frequency.
Price Trends
| Year |
Average Price per Treatment |
Notes |
| 2020 |
$[amount] |
Launch period |
| 2021 |
$[amount] |
Price stabilization |
| 2022 |
$[amount] |
Slight increase due to inflation, new dosing options |
Projected Price Trajectory (2023-2027)
| Year |
Expected Price per Treatment |
Assumptions |
| 2023 |
$[amount] |
Stable, with minor inflation adjustments |
| 2024 |
*$[amount]]\ |
Slight increase due to new indications or formulations |
| 2025 |
*$[amount]]\ |
Potential price reductions from biosimilars or generics in key markets |
| 2026 |
*$[amount]]\ |
Market saturation and pricing pressures |
| 2027 |
*$[amount]]\ |
Full biosimilar competition expected, potential downward adjustment |
Note: Price assumptions based on historical trends, patent expiry timelines, and industry reports.
Factors Influencing Price Evolution
- Entry of biosimilar competitors, generally causing price reductions of 15-30% within 2-3 years after launch
- Regulatory decisions or new clinical trial results impacting perceived value
- Changes in healthcare policies affecting reimbursement or pricing caps
Regulatory and Patent Landscape
- Patent protection valid until [year], with approvals for [specific patents or patents pending]
- Pending biosimilar applications in [markets], with potential approval timelines between 2023-2025
Market Expansion Opportunities
- Additional indications such as [list indications] could expand the target population
- Geographic expansion into [countries/regions] where regulatory approval is pending or underway
- Companion diagnostic development to stratify responsive patient populations
Key Market Risks
- Patent cliffs and biosimilar competition
- Pricing pressure from payers and government programs
- Uncertain regulatory pathways for line extensions or new indications
Conclusion
NDC 21922-0069 maintains a market value of approximately $[current] per treatment course in the U.S., with prices projected to decrease modestly over the next few years due to biosimilar competition. The drug's growth depends on expanding indications, geographic market penetration, and healthcare policy shifts.
Key Takeaways
- The drug targets a sizable and growing patient population in oncology or immunology.
- Competitive pressures and patent expiries will influence future pricing.
- Price projections suggest a gradual decline due to biosimilar entries, with stabilization as new indications and markets develop.
- Market expansion hinges on regulatory approvals and innovation in companion diagnostics.
- Reimbursement strategies will significantly impact the real-world market pricing and accessibility.
FAQs
1. When is biosimilar competition expected for this drug?
Most biosimilars for similar biologics are expected around 2024-2025, with some already approved in specific markets.
2. How do regulatory decisions affect pricing?
Regulatory approvals for additional indications or line extensions can extend exclusivity, maintaining higher prices longer. Conversely, biosimilar approval reduces prices.
3. What is the potential for international market growth?
Emerging markets are establishing regulatory pathways, offering opportunities for slow but steady growth outside the U.S. and Europe.
4. How do recent clinical trial results influence market outlook?
Positive results reinforce market share and justify price stability; negative results may accelerate price reductions.
5. What strategies can manufacturers employ to extend product lifecycle?
Developing new indications, optimizing formulations, and securing reimbursement agreements address market competition and patent expiration impacts.
References
- Centers for Disease Control and Prevention. (2022). [Prevalence estimates].
- IQVIA. (2022). [Market Reports].
- U.S. Food and Drug Administration. (2023). [Approval notices and patent information].
- MarketWatch. (2023). [Pharmaceutical pricing trends].
- GlobalData. (2023). [Biologics and biosimilars outlook].
[Note: Placeholder texts such as "[Drug Name]" and "[amount]" should be cross-referenced with actual data sources for precision.]
